How Laureate’s Raised 2026 Outlook And Bigger Buybacks At Laureate Education (LAUR) Has Changed Its Investment Story

Laureate Education, Inc.

Laureate Education, Inc.

LAUR

0.00

  • In late July 2026, Laureate Education, Inc. reported second-quarter sales of US$615.86 million and net income of US$137.1 million, alongside higher first-half earnings and an updated full-year 2026 revenue outlook of US$1.92 billion to US$1.93 billion, implying 13% as-reported growth.
  • At the same time, Laureate expanded its share repurchase effort, having already bought back 13,863,000 shares for US$399.61 million and adding a further US$250 million authorization, highlighting management’s focus on capital returns alongside improving profitability.
  • We’ll now explore how Laureate’s raised 2026 revenue guidance reshapes the earlier investment narrative built around Latin American expansion and digital learning.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Laureate Education Investment Narrative Recap

To own Laureate, you need to believe its focus on Latin American higher education and digital programs can keep enrollment and pricing resilient despite local volatility. The updated 2026 revenue guidance to US$1.92–1.93 billion reinforces the near term growth story, while the biggest risk still sits with concentrated exposure to Mexico and Peru, where regulatory or macro shocks could quickly affect demand and reported results. The latest update does not remove that risk, but it does not materially increase it either.

The most directly relevant announcement is the raised 2026 revenue outlook to 13% as reported growth, coming alongside stronger second quarter and first half earnings. This tighter, higher range gives investors a clearer reference point for assessing whether campus expansion and digital learning initiatives are translating into sustained top line progress, which is critical for supporting the current investment case built around Latin American growth and improving profitability.

Yet even with higher guidance, investors should be aware that concentrated exposure to Mexico and Peru could still leave Laureate vulnerable to shifts in...

Laureate Education's narrative projects $2.3 billion revenue and $373.6 million earnings by 2029. This requires 9.1% yearly revenue growth and about a $93.8 million earnings increase from $279.8 million today.

Uncover how Laureate Education's forecasts yield a $40.25 fair value, a 5% upside to its current price.

Exploring Other Perspectives

LAUR 1-Year Stock Price Chart
LAUR 1-Year Stock Price Chart

The most optimistic analysts were already projecting around US$2.4 billion of revenue and roughly US$429 million of earnings by 2029, so this guidance raise could either support or challenge those bullish views depending on how you weigh that faster growing online segment against the demographic and regulatory risks they highlight.

Explore 4 other fair value estimates on Laureate Education - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Laureate Education research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free Laureate Education research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Laureate Education's overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

  • The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
  • Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.